Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Open access

Abstract

BACKGROUND: In Parkinson disease (PD), the benefit of levodopa therapy becomes less marked over time, perhaps because degeneration of nigrostrial neurons causes progressive loss of aromatic l-amino acid decarboxylase (AADC), the enzyme that converts levodopa into dopamine. In a primate model of PD, intrastriatal infusion of an adeno-associated viral type 2 vector containing the human AADC gene (AAV-hAADC) results in robust response to low-dose levodopa without the side effects associated with higher doses. These data prompted a clinical trial. METHODS: Patients with moderately advanced PD received bilateral intraputaminal infusion of AAV-hAADC vector. Low-dose and high-dose cohorts (5 patients in each) were studied using standardized clinical rating scales at baseline and 6 months. PET scans using the AADC tracer [(18)F]fluoro-L-m-tyrosine (FMT) were performed as a measure of gene expression. RESULTS: The gene therapy was well tolerated, but 1 symptomatic and 2 asymptomatic intracranial hemorrhages followed the operative procedure. Total and motor rating scales improved in both cohorts. Motor diaries also showed increased on-time and reduced off-time without increased "on" time dyskinesia. At 6 months, FMT PET showed a 30% increase of putaminal uptake in the low-dose cohort and a 75% increase in the high-dose cohort. CONCLUSION: This study provides class IV evidence that bilateral intrastriatal infusion of adeno-associated viral type 2 vector containing the human AADC gene improves mean scores on the Unified Parkinson's Disease Rating Scale by approximately 30% in the on and off states, but the surgical procedure may be associated with an increased risk of intracranial hemorrhage and self-limited headache.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181c29356

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 452

Metadata

Authors
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J.
Affiliations
University of California, San Francisco (US)
Corresponding author
Aminoff, M. J.
Venue
Neurology
Published
2009-11-17
Volume
73
Issue
20
Pages
1662-1669
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2141355937
Cited by
445
References
20
Citations by year
2026: 18 · 2025: 25 · 2024: 31 · 2023: 16 · 2022: 19 · 2021: 24 · 2020: 21 · 2019: 25 · 2018: 27 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 25 · 2013: 35 · 2012: 35
FWCI
23.68
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Energy (FG02-08ER64699)
  • Lupus Research Alliance
  • Eisai
  • National Institutes of Health (1s10rr023051-01)
  • University of California, San Francisco
  • Avid Radiopharmaceuticals
  • National Institute on Aging (AG027984, R01AG027984, R41AG030241, AG 024904, R01AG027859, AG027859)
  • National Cancer Institute (R01 CA94253-01, R01CA135358, R01CA119414, R01CA135626, U54 CA 90788, R01CA094253, U54CA090788)
  • National Institute of Neurological Disorders and Stroke (R01NS037167, R01 NS-37167, R01NS046487, U10NS044460)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB000482)
  • National Center for Research Resources (S10 RR023051)
  • Lawrence Berkeley National Laboratory
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, aromatic L-amino acid decarboxylase, levodopa, intracranial hemorrhage, safety and tolerability, gene expression, motor symptoms, levodopa-induced dyskinesia
MeSH terms
Aged, Aromatic-L-Amino-Acid Decarboxylases, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Putamen, Severity of Illness Index, Time Factors, Genetic Therapy, Cohort Studies, Treatment Outcome, Neurosurgical Procedures, Intracranial Hemorrhages, Dyskinesias, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181c29356
The paper
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181c29356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.